Qatar Biobank, Qatar

Registration Status: In Progress

Objective: What is Biobank Qatar? â€¢ Biobank Qatar is a center within Qatar Foundationâ€™s Biomedical Research Institute. It has been created by Qatar Foundation in partnership with the Supreme Council of Health and working with Hamad Medical Corporation, as a national resource for biomedical research. â€¢ Through its collection of samples and information on health and lifestyle from large numbers of participants from the population of Qatar, Biobank Qatar will make vital health research possible for the scientists and researchers in Qatar, the region and the world. â€¢ Biobank Qatar is a globally unique resource that will advance Qatarâ€™s journey towards becoming a regional hub for medical research and expertise and will help Qatar contribute to the development of biomedical knowledge globally. What we do â€¢ Biobank Qatar is recruiting large numbers of the Qatari population to contribute biological samples and information about their health and lifestyle. â€¢ Biobank Qatar will serve as a platform and driver of biomedical research primarily in Qatar, although it may support research conducted outside of Qatar where there is potential to achieve benefits for the population of Qatar.

Registered Biobank Name	Qatar Biobank
Biobank Leader	Dr. Asma Althani
Country	Qatar
Email for biobank inquiries	nafifi@qf.org.qa
Principal Investigator	Dr. Nahla Afifi
Website	www.qatarbiobank.org.qa
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).